Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Cybin Inc (CYBN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cybin's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.368 -0.007    -1.97%
16:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
0.365
-0.003
-0.842%
20:00:00 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,645,037
  • Bid/Ask: 0.363 / 0.365
  • Day's Range: 0.362 - 0.380
Cybin 0.368 -0.007 -1.97%

CYBN Ratios

 
Assess the performance of Cybin (CYBN). This table contains core financial ratios such as Price-to-Earnings (P/E ratio), Return-On-Investment (ROI), Earnings per share (EPS), Dividend yield and others based on Cybin Inc's latest financial reports. Compare the performance metrics of Cybin (CYBN) against the industry averages.
InvestingPro Advanced Ratios
Name Company Industry
   
P/E Ratio TTM -5.54 0.72
Price to Sales TTM - 716.27
Price to Cash Flow MRQ -2.21 2.4
Price to Free Cash Flow TTM -6.61 -13.21
Price to Book MRQ 3.22 4.31
Price to Tangible Book MRQ 9.32 1.69
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM - -4,938.09
Gross Margin 5YA -36% -983.54
Operating margin TTM 0% -9,610
Operating margin 5YA -3,592.01% -2,917.21
Pretax margin TTM 0% -9,099.6
Pretax margin 5YA -3,729.17% -1,740.8
Net Profit margin TTM 0% -9,093.98
Net Profit margin 5YA -3,729.17% -4,772.71
   
Revenue/Share TTM - 38.23
Basic EPS ANN -0.26 7.33
Diluted EPS ANN -0.26 6.96
Book Value/Share MRQ 0.29 63.04
Tangible Book Value/Share MRQ 0.1 47.77
Cash/Share MRQ 0.09 17.5
Cash Flow/Share TTM -0.14 9.15
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM -79.36% -39.63
Return on Equity 5YA -66.27% -66.96
Return on Assets TTM -74% -13.87
Return on Assets 5YA -79.61% -11.93
Return on Investment TTM -64.35% -8.99
Return on Investment 5YA -73.23% -8.37
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ -59.83% -20.73
EPS(TTM) vs TTM 1 Yr. Ago TTM -3.72% -71.86
5 Year EPS Growth 5YA 0% 6.03
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ 0% 476.19
Sales (TTM) vs TTM 1 Yr. Ago TTM 0% 52.24
5 Year Sales Growth 5YA 0% 31.23
5 Year Capital Spending Growth 5YA 0% 20.56
   
Quick Ratio MRQ 4.61 6
Current Ratio MRQ 5.76 6.34
LT Debt to Equity MRQ - 39.81
Total Debt to Equity MRQ 0.3% 1.98
Efficiency    
Asset Turnover TTM - 0.32
Inventory Turnover TTM - 5.96
Revenue/Employee TTM - 608.57K
Net Income/Employee TTM -1.41M -401.07K
Receivable Turnover TTM - 6.7
   
Dividend Yield ANN - 0.03
Dividend Yield 5 Year Avg. 5YA - 0.03
Dividend Growth Rate ANN 0% 0.8
Payout Ratio TTM - 1.83
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced valuation and financial ratios for in-depth analysis of company financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CYBN Comments

Write your thoughts about Cybin Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
nelson Dias
nelson Dias Oct 23, 2023 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
love this stock it will be in much demand
Deb Fisler
Deb Fisler Sep 09, 2022 3:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Last week I was way-up on this dog don't bother with it.
Deb Fisler
Deb Fisler Sep 06, 2022 4:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Unfortunately little obscure stocks with big potential are at the mercy of greedy skimmers
Deb Fisler
Deb Fisler Sep 06, 2022 3:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I've seen this pattern before...skimmers...it'll never be the stock that it's capable of being because they skim off the top every time it goes over $1.00 don't bother with this inexpensive one.
Hyborian War
HyborianWar Apr 04, 2022 3:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🍄
Dec 08, 2021 9:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
http://crweworld.com/article/news-provided-by-business-wire/2225622/cybin-confirms-scientific-advice-meeting-with-uk-medical-and-healthcare-products-regulatory-agency-for-lead-candidate-cyb003-for-the-treatment-of-major-depressive-disorder-and-alcohol-usen-disorder
Trace Jared
Trace Jared Jan 15, 2021 2:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what's with the big jump today
Trace Jared
Trace Jared Jan 15, 2021 2:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what's with the big jump today ?
James Almeida Stille
James Almeida Stille Jan 15, 2021 2:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Canadian investment bank Stifel GMP has released new research on psychedelics and both $FTRP and $CYBN Their research calls psychedelic medicines a "possible disruptor to legacy treatments" and shares their perspective that there is an "accelerating wave of psychedelic reform." CYBN was given a speculative buy rating and a $5 price target. The report can be found with a quick google search.
James Almeida Stille
James Almeida Stille Jan 15, 2021 2:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
At this point, I'm not a fan of FTRP due to the fact that its trading on such low daily volume. Also, the Horizon ETF (PSYK) is about to launch and they might have been buying up CYBN on Friday. Not giving advice on what to do. Always do your own DD. Good luck!
James Almeida Stille
James Almeida Stille Jan 08, 2021 2:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This one is my favourite companies in this sector at the moment. One of the side effects of psilocybin mushrooms in higher dosages is mild nausea. Their sublingual film drug (psilotonin) which is about to enter phase 2a bypasses the stomach, liver etc. In other words, everyone else is working on pill formulations that have to be digested while these folks seem to have a brilliant product in the making. Anyone else here holding long? If so, what are your reasons for liking this one?
Shawn Gauvreau
Shawn Gauvreau Jan 08, 2021 2:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Holding long, MMED is at the fore front in this ground breaking industry. This is just the beginning. I predict this stock to be + $10.00 within two years and + $20.00 after first FDA approval
James Almeida Stille
James Almeida Stille Jan 08, 2021 2:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Shawn Gauvreau  CYBN is undervalued compared to its peers imo and I have a feeling that people are sleeping on this one. If you haven't read over their investor presentations, I highly recommend going to view them on their website. Keep in mind that these drugs are going to be used in clinics with psychotherapy integration to help the patients find what they really need to take away from their mystical experience in order to heal their depression and regain control of their lives. Just my opinion here, everyone must do their own DD. Good luck!
Ssss Sssss
Ssss Sssss Dec 14, 2020 7:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yes, bought some for $2.22
David Beer
David Beer Dec 14, 2020 7:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
not looking so great now is it,
Ssss Sssss
Ssss Sssss Dec 14, 2020 7:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
David Beer  sold @ 2.32. now looking to enter @ 1.66
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email